Gift, page-19

This actually seems like a decent stock, which is saying something given my post history in terms of analysing.

6.26M in assets, of which 1.33 is hard cash.
Liabilities aren't out of control and are basically met.

There's likely a chance for a some search for funding shortly but that will likely just present an opportunity to get more cheaper if it happens.

Revenue is already 3M, on epichem, if the dog cancer treatment becomes a success then I would say the revenues will expand from 3M yearly to maybe up to 12M yearly in the most optimistic scenario.

(12 Mill per year, @ 10% as earnings = 1.2M in profit), to get that kind of return from the safest type of investment you'd need a good 80Million. (ie; if they were already making 1.2 M in profit a year, you could justify 80M market cap)

The chance of them succeeding is very conservatively around 10%. Discounting that from the value: 80Mill x 10% = 8Mill ie; the current price is spot on; there is no hype or inflation yet you're buying the company at pretty much it's true worth.

As more information comes out towards the success of the Phase 2 trials on canines that probability will increase from 10% ->100% and mkt cap will go from it's current level, to 50-100M, based on hype, future prospects with human trials etc.

DYOR, ofcourse. But Im in this one.